62 related articles for article (PubMed ID: 37527977)
1. Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era.
Patel AA; Yoon JJ; Johnston H; Davidson MB; Shallis RM; Chen EC; Burkart M; Oh TS; Iyer SG; Madarang E; Muthiah C; Gross I; Dean R; Kassner J; Viswabandya A; Madero-Marroquin R; Rampal RK; Guru Murthy GS; Bradley TJ; Abaza Y; Garcia JS; Gupta V; Pettit KM; Cursio JF; Odenike O
Blood Adv; 2024 May; ():. PubMed ID: 38739724
[TBL] [Abstract][Full Text] [Related]
2. CPX-351 (Vyxeos™) treatment in blast-phase myeloproliferative neoplasm (MPN-BP): real-world experience in 12 consecutive cases.
Ilyas R; McCullough K; Badar T; Patnaik MM; Alkhateeb H; Mangaonkar A; Pardanani A; Tefferi A; Gangat N
Blood Cancer J; 2023 Feb; 13(1):26. PubMed ID: 36797234
[No Abstract] [Full Text] [Related]
3. How I treat myeloproliferative neoplasms in pregnancy.
Robinson S; Ragheb M; Harrison C
Blood; 2024 Feb; 143(9):777-785. PubMed ID: 38145575
[TBL] [Abstract][Full Text] [Related]
4. Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms.
Grockowiak E; Korn C; Rak J; Lysenko V; Hallou A; Panvini FM; Williams M; Fielding C; Fang Z; Khatib-Massalha E; García-García A; Li J; Khorshed RA; González-Antón S; Baxter EJ; Kusumbe A; Wilkins BS; Green A; Simons BD; Harrison CN; Green AR; Lo Celso C; Theocharides APA; Méndez-Ferrer S
Nat Cancer; 2023 Aug; 4(8):1193-1209. PubMed ID: 37550517
[TBL] [Abstract][Full Text] [Related]
5. IDH1/2 inhibitor monotherapy in blast-phase myeloproliferative neoplasms: A multicentre experience.
Gangat N; Ajufo H; Abdelmagid M; Karrar O; McCullough K; Badar T; Foran J; Palmer J; Alkhateeb H; Mangaonkar A; Kuykendall A; Rampal RK; Tefferi A
Br J Haematol; 2023 Nov; 203(3):e87-e92. PubMed ID: 37537750
[No Abstract] [Full Text] [Related]
6. Sodium-glucose co-transporter-2 inhibitor treatment in essential thrombocythemia: Impact on hemoglobin/hematocrit levels and outcomes among 11 consecutive patients.
Gangat N; Reichard K; Tefferi A
Am J Hematol; 2023 Nov; 98(11):E298-E300. PubMed ID: 37552702
[No Abstract] [Full Text] [Related]
7. Contribution of lowered hemoglobin threshold value in the diagnosis of polycythemia vera: Comparison of 2016 and 2008 WHO criteria.
Gulturk E; Yilmaz D; Sonmezoz GB; Yildirim ES
Medicine (Baltimore); 2023 Aug; 102(31):e34462. PubMed ID: 37543796
[TBL] [Abstract][Full Text] [Related]
8. Silent Thyroiditis Associated with Ropeginterferon α-2b in a Patient with Polycythemia Vera.
Kirito K
Intern Med; 2024 Mar; 63(6):843-846. PubMed ID: 37532547
[TBL] [Abstract][Full Text] [Related]
9. Mutational landscape of blast phase myeloproliferative neoplasms (MPN-BP) and antecedent MPN.
Pasca S; Chifotides HT; Verstovsek S; Bose P
Int Rev Cell Mol Biol; 2022; 366():83-124. PubMed ID: 35153007
[TBL] [Abstract][Full Text] [Related]
10. Accelerated and Blast Phase Myeloproliferative Neoplasms.
Jain T; Rampal RK
Hematol Oncol Clin North Am; 2021 Apr; 35(2):325-335. PubMed ID: 33641872
[TBL] [Abstract][Full Text] [Related]
11. Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
Mahdi D; Spiers J; Rampotas A; Polverelli N; McLornan DP
Br J Haematol; 2023 Oct; 203(2):169-181. PubMed ID: 37527977
[TBL] [Abstract][Full Text] [Related]
12. Accelerated Phase of Myeloproliferative Neoplasms.
Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
[TBL] [Abstract][Full Text] [Related]
13. Accelerated and blast phase myeloproliferative neoplasms.
Saliba AN; Gangat N
Best Pract Res Clin Haematol; 2022 Jun; 35(2):101379. PubMed ID: 36333070
[TBL] [Abstract][Full Text] [Related]
14. Addressing the challenges of accelerated and blast phase myeloproliferative neoplasms in 2022 and beyond.
Saha C; Attwell L; Harrison CN; McLornan DP
Blood Rev; 2022 Sep; 55():100947. PubMed ID: 35241294
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
